Innovation and Technology for Biosimilar Development

A biosimilar is an organic item very like an affirmed natural item, known as a kind of perspective item, with no clinically significant contrasts as far as wellbeing and viability. In the U.S., if a natural compound exhibits practically identical information to a U.S. Nourishment and Drug Administration (FDA)- authorized item from expository, preclinical and clinical reviews, it will be acknowledged as a biosimilar after termination of trend-setter licenses through a curtailed course. Tradable natural items are likewise Biosimilars, however should meet extra criteria to coordinate the reference item. Interchangeable can be substituted for the reference item without a medicine from a social insurance supplier.

 

  • Biosimilar Product Reimbursement and Pricing
  • Biosimilar Regulatory Updates and Legal Implications
  • Biosimilar Market Access and Commercialization

Related Conference of Innovation and Technology for Biosimilar Development

August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
August 29-30, 2018 |

International Conference and Exhibition on Drug Safety & Pharmacovigilance

Park Inn By Radisson Toronto Airport West, 175 Derry Road East, Mississauga, ON, L5T 2Z7, Canada
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 14-15 | 2018

13th International Conference on Biosimilars and Biologics

Lisbon | Portugal

Innovation and Technology for Biosimilar Development Conference Speakers

Recommended Sessions

Related Journals

Are you interested in